Corona Remedies Limited has announced its quarterly earnings conference call to discuss the company's Q2FY26 financial performance. The pharmaceutical company informed stock exchanges about the scheduled investor interaction through a regulatory filing under SEBI Listing Regulations.

Conference Call Details

The earnings conference call has been scheduled with the following specifications:

Management Participation

The conference call will feature senior management representatives from Corona Remedies Limited. Key participants include Mr. Nirav Mehta, Managing Director & CEO, Mr. Ankur Mehta, Joint Managing Director, and Mr. Bhavin Bhagat, Chief Financial Officer. The senior management team will be available to discuss the company's financial performance and address investor queries.

Access Information

Investors and analysts can participate in the conference call through multiple access options. The universal dial-in numbers are +91-22-6280 1366 and +91-22-7115 8267. International participants can use toll-free numbers for USA (1 866 746 2133), UK (0 808 101 1573), Singapore (800 101 2045), and Hong Kong (800 964 448). Participants are advised to dial-in 10 minutes prior to the scheduled time to ensure proper connection.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Chetna Dharajiya signed the regulatory filing on December 30, 2025. The intimation has also been made available on the company's website at www.coronaremedies.com .

Contact Information

For further information regarding the conference call, investors can contact JM Financial Institutional Securities representatives. The contact persons include Mr. Amey Chalke (+91-22-6630 3056), Mr. Abin Benny (+91-22-6970 3621), and Mr. Gourav Bhama (+91-22-6970 3679). JM Financial Institutional Securities Limited is organizing the earnings call as part of their institutional services.

Corona Remedies Limited has officially commenced additional commercial production of tablets and capsules at its Bhayla manufacturing facility on December 22, 2025, at approximately 10:00 a.m., marking a significant milestone in the company's manufacturing expansion strategy.

Capacity Enhancement Details

The pharmaceutical company has successfully increased its production capabilities at the Bhayla facility with substantial capacity additions. The expansion adds 400 million units to the installed capacity and 240 million units to the available capacity.

Production Performance

As of March 31, 2025, the Bhayla facility demonstrated strong operational efficiency with actual production of 561.49 million units against an available capacity of 600 million units, achieving a capacity utilization rate of 93.58%. This high utilization rate reflects the company's effective manufacturing operations and market demand.

Strategic Expansion Impact

The additional commercial production represents a significant milestone in Corona Remedies' strategic expansion plans. The company expects this capacity enhancement to augment upcoming market demands, enhance in-house production capabilities, and improve supply chain agility.

Financial Strategy

The capacity expansion has been entirely funded through internal accruals, highlighting Corona Remedies' strong financial position and self-sustaining growth approach. This internal funding strategy demonstrates the company's ability to finance significant operational expansions without external borrowing or equity dilution.